EMC Capital Management Has $270,000 Position in Medpace Holdings, Inc. (NASDAQ:MEDP)

EMC Capital Management cut its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 67.5% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 813 shares of the company’s stock after selling 1,687 shares during the period. EMC Capital Management’s holdings in Medpace were worth $270,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Gries Financial LLC bought a new stake in Medpace in the fourth quarter valued at approximately $212,000. Swedbank AB lifted its position in shares of Medpace by 245.5% in the 4th quarter. Swedbank AB now owns 77,400 shares of the company’s stock worth $25,715,000 after purchasing an additional 55,000 shares during the period. R Squared Ltd bought a new stake in shares of Medpace in the 4th quarter valued at $30,000. Pacer Advisors Inc. increased its position in shares of Medpace by 40.8% during the fourth quarter. Pacer Advisors Inc. now owns 12,485 shares of the company’s stock worth $4,148,000 after buying an additional 3,616 shares during the period. Finally, Blue Trust Inc. raised its stake in Medpace by 21.5% during the fourth quarter. Blue Trust Inc. now owns 808 shares of the company’s stock worth $270,000 after buying an additional 143 shares during the last quarter. 77.98% of the stock is owned by institutional investors.

Analysts Set New Price Targets

MEDP has been the topic of a number of research analyst reports. William Blair reaffirmed an “outperform” rating on shares of Medpace in a research report on Tuesday, October 22nd. Baird R W downgraded Medpace from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 23rd. Robert W. Baird lifted their price objective on shares of Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a report on Monday. Truist Financial decreased their price target on Medpace from $415.00 to $397.00 and set a “hold” rating for the company in a report on Monday, October 14th. Finally, TD Cowen decreased their price objective on shares of Medpace from $413.00 to $372.00 and set a “buy” rating for the company in a research note on Wednesday, October 23rd. Seven research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Medpace currently has an average rating of “Hold” and an average price target of $381.44.

Medpace Stock Performance

Medpace stock traded up $7.92 during mid-day trading on Thursday, reaching $350.94. The company’s stock had a trading volume of 4,153 shares, compared to its average volume of 202,115. The firm’s fifty day moving average price is $341.77 and its two-hundred day moving average price is $353.45. Medpace Holdings, Inc. has a 12-month low of $286.76 and a 12-month high of $459.77. The company has a market capitalization of $10.91 billion, a P/E ratio of 30.81, a PEG ratio of 1.77 and a beta of 1.36.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.